Abstract
Objectives: Patients with coronary artery aneurysms are at risk for thrombotic and stenotic complications later in their lives. The longitudinal changes of medium-sized coronary aneurysms caused by Kawasaki disease (KD) and their long-term outcome are still unclear in Taiwan. Methods: We retrospectively reviewed medical records of KD patients with medium-sized coronary aneurysms (4-8mm). The longitudinal change of coronary diameters were re-evaluated by domestic coronary z score calculator. The coronary artery diametes were transformed to standard deviation units from the mean (Z-score) normalized for body surface area. We also look for the potential risk factors for the persistence of coronary lesions. Results: Between 1983 and 2012, 56 KD patients suffered from medium aneurysms. The male to female ratio was 41:15. The mean age of disease onset was 2.13 years old, and 39.3% (22 of 56) was diagnosed at below 1 year old. The mean follow up duration was 8.2 years. No death occurred in this group of patient, and only one patient with persistent coronary aneurysm and stenosis/calcification had clinical evidence of myocardial ischemia. However, coronary aneurysms persisted in 24 (42.8%) patients and were associated with stenosis in 8 patients (14.3%), and calcification in 4 patients (7.1%). The coronary aneurysm persistence-free survival rates at 6 months, and 1, 2, 5 years after KD onset were 81%, 69%, 52%, 43%, respectively. Chi-square analysis revealed KD patients with history of ever deterioration of coronary Z score were significantly associated with the persistence of coronary aneurysms ( P = 0.0125). However, the initial aneurysm Z score (+4.43 vs +4.49), male gender or IVIG use were not risk factors to the persistence of coronary aneurysms. Conclusion: The prognosis of Kawasaki disease patient who developed medium size coronary aneurysm was good. However, those with ever deterioration of coronary Z scores were high risk group to have persistent coronary aneurysms. Specific therapies to promote vascular health in these patients should be advocated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.